Resistant hypertension: A frequent and ominous finding among hypertensive patients with atherothrombosis

Dharam J. Kumbhani, P. Gabriel Steg, Christopher P. Cannon, Kim A. Eagle, Sidney C. Smith, Kevin Crowley, Shinya Goto, E. Magnus Ohman, George L. Bakris, Todd S. Perlstein, Scott Kinlay, Deepak L. Bhatt

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

AimsThe effect of resistant hypertension on outcomes in patients with atherothrombotic disease is currently unknown. Accordingly, we sought to determine the prevalence and outcomes of resistant hypertension in stable hypertensive outpatients with subclinical or established atherothombotic disease enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry.Methods and resultsResistant hypertension was defined as a blood pressure ≥140/90 mmHg at baseline (≥130/80 mmHg if diabetes/renal insufficiency) with the use of ≥3 antihypertensive medications, including a diuretic. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke at 4 years. A total of 53 530 hypertensive patients were included. The prevalence of resistant hypertension was 12.7%; 6.2% on 3 antihypertensive agents, 4.6% on 4 agents, and 1.9% on ≥5 agents (mean: 4.7 ± 0.8). In addition to a diuretic, these patients were being treated mostly with ACE-inhibitors/angiotensin receptor blockers (90.1%), beta-blockers (67.0%), and calcium channel blockers (50.8%). Patients with resistant hypertension had a higher risk of the primary endpoint on multivariable analysis [hazard ratio (HR) 1.11, 95% confidence interval (CI) 1.02-1.20; P = 0.017], including an increased non-fatal stroke risk (HR: 1.26; 95% CI: 1.10-1.45; P = 0.0008). Hospitalizations due to congestive heart failure were higher (P < 0.0001). Patients on ≥5 agents had a higher adjusted risk for the primary endpoint when compared with those on ≤3 agents (P = 0.03).ConclusionThe presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.

Original languageEnglish (US)
Pages (from-to)1204-1214
Number of pages11
JournalEuropean Heart Journal
Volume34
Issue number16
DOIs
StatePublished - Apr 21 2013

Fingerprint

Hypertension
Diuretics
Antihypertensive Agents
Stroke
Confidence Intervals
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Renal Insufficiency
Registries
Hospitalization
Outpatients
Heart Failure
Odds Ratio
Myocardial Infarction
Blood Pressure
Health

Keywords

  • Atherosclerosis
  • Heart failure
  • Mortality
  • Resistant hypertension
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Resistant hypertension : A frequent and ominous finding among hypertensive patients with atherothrombosis. / Kumbhani, Dharam J.; Steg, P. Gabriel; Cannon, Christopher P.; Eagle, Kim A.; Smith, Sidney C.; Crowley, Kevin; Goto, Shinya; Ohman, E. Magnus; Bakris, George L.; Perlstein, Todd S.; Kinlay, Scott; Bhatt, Deepak L.

In: European Heart Journal, Vol. 34, No. 16, 21.04.2013, p. 1204-1214.

Research output: Contribution to journalArticle

Kumbhani, DJ, Steg, PG, Cannon, CP, Eagle, KA, Smith, SC, Crowley, K, Goto, S, Ohman, EM, Bakris, GL, Perlstein, TS, Kinlay, S & Bhatt, DL 2013, 'Resistant hypertension: A frequent and ominous finding among hypertensive patients with atherothrombosis', European Heart Journal, vol. 34, no. 16, pp. 1204-1214. https://doi.org/10.1093/eurheartj/ehs368
Kumbhani, Dharam J. ; Steg, P. Gabriel ; Cannon, Christopher P. ; Eagle, Kim A. ; Smith, Sidney C. ; Crowley, Kevin ; Goto, Shinya ; Ohman, E. Magnus ; Bakris, George L. ; Perlstein, Todd S. ; Kinlay, Scott ; Bhatt, Deepak L. / Resistant hypertension : A frequent and ominous finding among hypertensive patients with atherothrombosis. In: European Heart Journal. 2013 ; Vol. 34, No. 16. pp. 1204-1214.
@article{5ea8b1e0973449a583c5877b72bdcc65,
title = "Resistant hypertension: A frequent and ominous finding among hypertensive patients with atherothrombosis",
abstract = "AimsThe effect of resistant hypertension on outcomes in patients with atherothrombotic disease is currently unknown. Accordingly, we sought to determine the prevalence and outcomes of resistant hypertension in stable hypertensive outpatients with subclinical or established atherothombotic disease enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry.Methods and resultsResistant hypertension was defined as a blood pressure ≥140/90 mmHg at baseline (≥130/80 mmHg if diabetes/renal insufficiency) with the use of ≥3 antihypertensive medications, including a diuretic. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke at 4 years. A total of 53 530 hypertensive patients were included. The prevalence of resistant hypertension was 12.7{\%}; 6.2{\%} on 3 antihypertensive agents, 4.6{\%} on 4 agents, and 1.9{\%} on ≥5 agents (mean: 4.7 ± 0.8). In addition to a diuretic, these patients were being treated mostly with ACE-inhibitors/angiotensin receptor blockers (90.1{\%}), beta-blockers (67.0{\%}), and calcium channel blockers (50.8{\%}). Patients with resistant hypertension had a higher risk of the primary endpoint on multivariable analysis [hazard ratio (HR) 1.11, 95{\%} confidence interval (CI) 1.02-1.20; P = 0.017], including an increased non-fatal stroke risk (HR: 1.26; 95{\%} CI: 1.10-1.45; P = 0.0008). Hospitalizations due to congestive heart failure were higher (P < 0.0001). Patients on ≥5 agents had a higher adjusted risk for the primary endpoint when compared with those on ≤3 agents (P = 0.03).ConclusionThe presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.",
keywords = "Atherosclerosis, Heart failure, Mortality, Resistant hypertension, Stroke",
author = "Kumbhani, {Dharam J.} and Steg, {P. Gabriel} and Cannon, {Christopher P.} and Eagle, {Kim A.} and Smith, {Sidney C.} and Kevin Crowley and Shinya Goto and Ohman, {E. Magnus} and Bakris, {George L.} and Perlstein, {Todd S.} and Scott Kinlay and Bhatt, {Deepak L.}",
year = "2013",
month = "4",
day = "21",
doi = "10.1093/eurheartj/ehs368",
language = "English (US)",
volume = "34",
pages = "1204--1214",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Resistant hypertension

T2 - A frequent and ominous finding among hypertensive patients with atherothrombosis

AU - Kumbhani, Dharam J.

AU - Steg, P. Gabriel

AU - Cannon, Christopher P.

AU - Eagle, Kim A.

AU - Smith, Sidney C.

AU - Crowley, Kevin

AU - Goto, Shinya

AU - Ohman, E. Magnus

AU - Bakris, George L.

AU - Perlstein, Todd S.

AU - Kinlay, Scott

AU - Bhatt, Deepak L.

PY - 2013/4/21

Y1 - 2013/4/21

N2 - AimsThe effect of resistant hypertension on outcomes in patients with atherothrombotic disease is currently unknown. Accordingly, we sought to determine the prevalence and outcomes of resistant hypertension in stable hypertensive outpatients with subclinical or established atherothombotic disease enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry.Methods and resultsResistant hypertension was defined as a blood pressure ≥140/90 mmHg at baseline (≥130/80 mmHg if diabetes/renal insufficiency) with the use of ≥3 antihypertensive medications, including a diuretic. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke at 4 years. A total of 53 530 hypertensive patients were included. The prevalence of resistant hypertension was 12.7%; 6.2% on 3 antihypertensive agents, 4.6% on 4 agents, and 1.9% on ≥5 agents (mean: 4.7 ± 0.8). In addition to a diuretic, these patients were being treated mostly with ACE-inhibitors/angiotensin receptor blockers (90.1%), beta-blockers (67.0%), and calcium channel blockers (50.8%). Patients with resistant hypertension had a higher risk of the primary endpoint on multivariable analysis [hazard ratio (HR) 1.11, 95% confidence interval (CI) 1.02-1.20; P = 0.017], including an increased non-fatal stroke risk (HR: 1.26; 95% CI: 1.10-1.45; P = 0.0008). Hospitalizations due to congestive heart failure were higher (P < 0.0001). Patients on ≥5 agents had a higher adjusted risk for the primary endpoint when compared with those on ≤3 agents (P = 0.03).ConclusionThe presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.

AB - AimsThe effect of resistant hypertension on outcomes in patients with atherothrombotic disease is currently unknown. Accordingly, we sought to determine the prevalence and outcomes of resistant hypertension in stable hypertensive outpatients with subclinical or established atherothombotic disease enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry.Methods and resultsResistant hypertension was defined as a blood pressure ≥140/90 mmHg at baseline (≥130/80 mmHg if diabetes/renal insufficiency) with the use of ≥3 antihypertensive medications, including a diuretic. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke at 4 years. A total of 53 530 hypertensive patients were included. The prevalence of resistant hypertension was 12.7%; 6.2% on 3 antihypertensive agents, 4.6% on 4 agents, and 1.9% on ≥5 agents (mean: 4.7 ± 0.8). In addition to a diuretic, these patients were being treated mostly with ACE-inhibitors/angiotensin receptor blockers (90.1%), beta-blockers (67.0%), and calcium channel blockers (50.8%). Patients with resistant hypertension had a higher risk of the primary endpoint on multivariable analysis [hazard ratio (HR) 1.11, 95% confidence interval (CI) 1.02-1.20; P = 0.017], including an increased non-fatal stroke risk (HR: 1.26; 95% CI: 1.10-1.45; P = 0.0008). Hospitalizations due to congestive heart failure were higher (P < 0.0001). Patients on ≥5 agents had a higher adjusted risk for the primary endpoint when compared with those on ≤3 agents (P = 0.03).ConclusionThe presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.

KW - Atherosclerosis

KW - Heart failure

KW - Mortality

KW - Resistant hypertension

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84877634755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877634755&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehs368

DO - 10.1093/eurheartj/ehs368

M3 - Article

C2 - 23144048

AN - SCOPUS:84877634755

VL - 34

SP - 1204

EP - 1214

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 16

ER -